Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies. |
Novartis Pharma Services AG |
Humans |
CD19 CAR |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
Phase II study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis (dcSSc) |
Novartis Pharma Services AG |
Humans |
CD19 CAR |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia |
Novartis Pharma Services AG |
Humans |
Chimeric antigen receptor against CD19 |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina |
GenVec, Inc. |
Humans |
human VEGF121 |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha |
Pasteur Mérieux Connaught |
Humans |
HLA-A1 restricted CTL epitope of MAGE-1 and
MAGE-3 genes |
